

- Faizal Haji – Neglected Diseases: The Cost of Our Health Revolution**
- Feldmann, H., et al. (2002). Emerging and reemerging infectious diseases. *Medical microbiology and immunology*, 191, 63–74.
- Global Forum for Health Research. (2002). The 10/90 Report on Health Research 2001–2002. Global Forum for Health Research Publication.
- Henderson, D.A. (1998) Bioterrorism as a public health threat. *Emerging Infectious Diseases*, 4, 488–492.
- MacDonald, R., & Yamey, G. (2001). The cost to global health of drug company profits. *Western Journal of Medicine*, 174, 302–303.
- Médecins Sans Frontières Access to Essential Medicines Campaign, Drugs for Neglected Diseases Working Group. (2001). *Fatal Imbalance: The Crisis in Research and Development for Drugs for Neglected Diseases*. Publication.
- Morel, C.M. (2003). Neglected diseases: under-funded research and inadequate health interventions. *Science and Society*, 4(special issue), S35–S38.
- Sauerborn, R., Nitayaramphong, S., Gerhardus, A. (1999) Strategies to enhance the use of health systems research for health sector reform. *Tropical Medicine & International Health*, 4, 827–835.
- Trouiller, P., et al. (2002b). Drug development for neglected diseases: a deficient market and a public-health policy failure. *The Lancet*, 359, 2188–2194.
- Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., & Ford, N. (2002a). Drug development for neglected diseases: a deficient market and a public-health policy failure. *The Lancet*, 359, 2188–2194.
- World Health Organization. (2000a). Health: A precious asset. Accelerating follow-up to the World Summit for Social Development, proposal by the World Health Organization, WHO/HSD/HID/00.1. Geneva: World Health Organization Report.
- World Health Organization. (2000b). The World Health Report 2000 estimates for 1999, Mortality by sex, cause and WHO Regions. Geneva: World Health Organization, 2000.
- Yamey, G. (2002). The world's most neglected diseases Ignored by the pharmaceutical industry and by public-private partnerships. *British Medical Journal*, 325, 176–177.
- Maria-Alexandra Petre - Microencapsulated Non-Autologous Cells: The Benevolent Trojan Horse**
- Campbell, N.A., & Reece, J.B. (2001). *Biology* (6th ed.). Toronto: Benjamin Cummings.
- Dhoot, N. (2002). Microencapsulation for therapeutic applications. Retrieved January 3, 2004, from DSapece database.
- Microencapsulation Gene Therapy Group Homepage. (1997, October 23). Retrieved November 17, 2003, from <http://www.fhs.mcmaster.ca/gene/overview.htm>
- Orive, G., Gascon, A.R., Hernandez, R.M., Igartua, M., & Pedraz, L.J. (2003). Cell microencapsulation technology for biomedical purposes: novel insights and challenges. *Trends in Pharmacological Sciences*, 24, 207–210.
- Abdullah Alabousi, Waqas Kayani, Soroush Seifi, Samer Dabbo - LDL, HDL, and the Battle Against Heart Disease**
- Aiello, R.J., Brees, D., Francone, O.L. (2003). ABCA1-deficient mice: insights into the role of monocyte lipid efflux in HDL formation and inflammation. *Arteriosclerosis Thrombosis and Vascular Biology*, 23, 972–980.
- Anderson, C.S., Jamrozik, K.D., Broadhurst, R.J., & Stewart-Wynne, E.G. (1994). Predicting Survival for One Year Among Different Subtypes of Stroke. *Stroke*, 25, 1935–1944.
- Attie, A., Kastelein, J., & Hayden, M. (2001). Pivotal Role of ABCA1 in Reverse Cholesterol Transport Influencing HDL Levels and Susceptibility to Atherosclerosis. *Journal of Lipid Res.* 42, 1717–1726.
- Ballantyne, C. (2000). HDL and reverse cholesterol transport. Retrieved February 12, 2004, from <http://www.lipidsonline.org>
- Ezekowitz, J.A., Straus, S.E., Majumdar, S.R., & McAlister, F.A. (2003). *Stroke: Strategies for Primary Prevention*. *American Family Physician*, 68(12), 2379–2380.
- Hayden, M.R., Clee, S.M., Brooks-Wilson, A., Genest, J. Jr., Attie, A., Kastelein, J.J. (2000). Cholesterol efflux regulatory protein, Tangier disease and familial high density lipoprotein deficiency. *Current Opinion in Lipidology*, 11, 117–122.
- Hoeg, J., Santamarina-Fojo, S., & Berard, A. (1996). Over-expression of Lecithin: Cholesterol Acyltransferase in Transgenic Rabbits Prevents Diet-Induced Atherosclerosis, 93, 11448–11453.
- Iso, H., Jacobs, D.R., Wentworth, D., Neaton, J.D., & Cohen, J.D. (1989). Serum Cholesterol Levels and Six-Year Mortality From Stroke in 350,977 Men Screened for the Multiple Risk Factor Intervention Trial. *New England Journal of Medicine*, 320, 904–910.
- Kumar, R., Dahiya, J.S., Singh, D., & Nigam, P. (2001). Biotransformation of Cholesterol Using *Lactobacillus Bulgaricus* in a Glucose-Controlled Bioreactor. *Bioresource Technology*, 78(2), 209–11.
- Nissen, S.E., Tsunoda, T., Tuzcu, E., Schoenhagen, P., Cooper, C., Yasin, M., Eaton, G., Lauer, M., Sheldon, W., Grines, C., Halpern, S., Crowe, T., Blankenship, J., & Kerensky, R. (2003). Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary Syndromes: A Randomized Controlled Trial. *JAMA*, 290, 2292–2300.
- Rosuvastatin/Crestor®. (2003). Retrieved January 10, 2004, from <http://www.micromedex.com/products/ptquik/samples/Rosuvastatin.htm>
- Seidel, D. (2003). LDL-Aphaeresis in the Treatment of Coronary Heart Disease: Rationale for a Specific Adjuvant Therapy. *Zeitschrift für Kardiologie (German Journal of Cardiology)*, 92(3), III36–III27.
- Singaraja, R., Fiever, C., & Castro, G. (2002). Increased ABCA-I Activity Protects Against Atherosclerosis. *Journal of Clin Invest*, 110, 35–42.
- Strauss, S.E., Majumdar, S.R., & McAlister, F.A. (2002). New Evidence for Stroke Prevention. *JAMA*, 288, 1388–1395.
- Toth, P. (2003). Reverse Cholesterol Transport: High-density Lipoprotein's Magnificent Mile. *Current Atherosclerosis Reports*, 5(5), 386–393.
- Trigatti, B., Rigotti, A., & Braun, A. (2000). Cellular and Physiological Roles of SR-BI, a Lipoprotein Receptor Which Mediates Selective Lipid Uptake. *Biochim Biophys Acta*, 1529, 276–286.
- Vaisman, B., Lambert, G., & Amar, M. (2001). ABCA-I Over-expression Leads to Hyperalphalipoproteinemia and Increased Biliary Cholesterol Excretion in Transgenic Mice. *Journal of Clin Invest*, 180, 303–309.
- Zha, X., Gauthier, A., & Genest, L. (2003). Secretory Vesicular Transport from the Golgi is Altered During ATP-binding Cassette Protein AI (ABCA-I) Mediated Cholesterol Efflux. *Journal of Bio/Chem*, in press.
- Jonathan M. Ng - Ethical Issues Encountered During the SARS Crisis**
- Singer, P.A., Benatar, S.R., Bernstein, M., Daar, A.S., Dickens, B.M., MacRae, S.K., Upshur, R.E., Wright, L., & Shaul, R.Z. (2003). Ethics and SARS: lessons from Toronto. *BMJ*, 327, 1342–4.
- Brent Mollon – Preparing for the Next SARS Epidemic: Exploring Treatment Development and Vaccination Options**
- Anand, K., Ziebuhr, J., Wadhvani, P., Mesters, J.R., & Hilgenfeld, R. (2003). Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs [Electronic version]. *Science*, 300, 1763–1767.
- Bosch, B.J., van der Zee, R., de Haan, C.A.M., & Rottier, P.J.M. (2003). The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex [Electronic Version]. *Journal of Virology*, 77, 8801–8811.
- Campbell, N.A., & Reece, J.B. (2001). *Biology* (6th ed.). San Francisco: Benjamin Cummings.

- Chen, L.L., Ou, H.Y., Zhang, R., & Zhang, C.T. (2003). ZCURVE_CoV: a new system to recognize protein coding genes in coronavirus genomes, and its applications in analyzing SARS-CoV genomes [Electronic Version]. *Biochemical and Biophysical Research Communications*, 307, 382-388.
- Emanuel, E.J. (2003). The lessons of SARS. *Annals of Internal Medicine*, 139, 589-591.
- Enserink, M. (2003). Clues to the animal origins of SARS [Electronic Version]. *Science*, 300, 1251.
- Enserink, M., & Normile, D. (2003). Search for SARS origins stalls [Electronic Version]. *Science*, 302, 766-767.
- Groneberg, D.A., Zhang, L., Welte, T., Zabel, P., & Chung, K.F. (2003). Severe acute respiratory syndrome: global initiatives for disease diagnosis [Electronic Version]. *Q J Med*, 96, 845-852.
- Hawkey, P.M., Bhagani, S., & Gillespie, S.H. (2003). Severe acute respiratory syndrome (SARS): breathtaking progress. *Journal of Medical Microbiology*, 52, 609-613.
- Jenwitheesuk, E. & Samudrala, R. (2003). Identifying inhibitors of the SARS coronavirus proteinase [Electronic Version]. *Bioorganic & Medicinal Chemistry Letters*, 13, 3989-3992.
- Lai, M.M.C. et al. (2001). *Fields Virology* (4th ed.). Pennsylvania: Lippincott, Williams & Wilkins.
- McMaster University Health Sciences (2003). McMaster researchers race to SARS vaccine development [Electronic Version]. Retrieved November 15, 2003 from <http://www.fhs.mcmaster.ca/pubrel/sars.htm>
- Spiga, O., Bernini, A., Ciutti, A., Chiellini, S., Menciasci, N., Finetti, F., et al. (2003). Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein [Electronic Version]. *Biochemical and Biophysical Research Communications*, 310, 78-83.
- Stavrinides, J. & Guttman, D.S. (2004). Mosaic evolution of the severe acute respiratory syndrome coronavirus [Electronic Version]. *Journal of Virology*, 78, 76-82.
- World Health Organization. (2003). Severe acute respiratory syndrome (SARS): status of the outbreak and lessons for the immediate future [Electronic Version]. Retrieved December 29, 2003 from http://www.who.int/csr/media/sars_wha.pdf
- World Health Organization. (2003). Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003 [Electronic Version]. Retrieved December 1, 2003 from http://www.who.int/csr/sars/country/table2003_09_23/en/
- Yan, L., Velikanov, M., Flook, P., Zheng, W., Szalma, S., & Kahn, S. (2003). Assessment of putative protein targets derived from the SARS genome [Electronic Version]. *FEBS Letters*, 554, 257-263.
- Zeng, F.Y., Chan, C.W.M., Chan, M.N., Chen, J.D., Chow, K.Y.C., Hon, C.C., et al. (2003). The complete genome sequence of severe acute respiratory syndrome coronavirus strain HKU-39849 (HK-39) [Electronic Version]. *Experimental Biology and Medicine*, 228, 866-873.

Jayant Ramakrishna - The Mind of a Genius: An Exploration of Albert Einstein's Brain

- Anderson, B. & Harvey T. (1996). Alteration in Cortical Thickness and Neuronal Density in the Frontal Cortex of Albert Einstein. *Neurosci Lett.*, 210, 161-164.
- Diamond, M.C., Scheibel, A.B., Murphy, G.M., & Harvey, T. (1985). On the Brain of a Scientist: Albert Einstein. *Experimental Neurology*, 88, 198-204.
- Hines, T. (1998). Further on Einstein's Brain. *Experimental Neurology*, 150, 343-344.
- Kolb, Byan, & Whishaw, I.Q. (2001). *An Introduction to Brain and Behavior*. New York: Worth Publishers.
- Stensaas, S. & Millhouse, O.E. (n.d.). *Digital Slice of Life*. Retrieved January 25, 2004, from <http://medlib.med.utah.edu/kw/sol/sss/>
- Witelson, S.F., Kigar, D.L., & Harvey, T. (1999). The Exceptional Brain of Albert Einstein. *The Lancet*, 353, 2149-2153.

The McMaster Meducator Executive 2003-2004



Back Row (Left to Right): Christine Almeida, Jaron Chong, Grace Y. Wang, Sammy. H. Ali, Thien Huynh, Jennifer C. Tang, Nisha Sivagurunathan, Jeannette So, Soroush Seifi
 Front Row: Jonathan M. Ng, Albert Einstein, Abhishek Raut